Ian O. Ellis, MD, FRCPath
Dr. Ellis serves as Professor of Cancer Pathology, Division of Cancer and Stem Cells, School of Medicine, Nottingham University and is an Honorary Consultant Pathologist at Nottingham City Hospital. He is the father of the Nottingham grading system (also known as the Elston-Ellis grading system), used worldwide in histopathology, and is the author of nearly 600 peer-reviewed publications on breast cancer. His H factor is over 80. Dr. Ellis has been involved in the practice of pathology for over thirty-five years and has an international reputation in clinical and translational research in breast disease, particularly classification and molecular pathology of breast cancer and evaluation of prognostic factors. He was a member of the writing party and Chairman of the Invasive Cancer Subcommittee for the WHO Classification of Tumours of the Breast as well as a member of the IARC Working Group on Breast Cancer Screening. In 2010, he was named as one of the top 20 most influential people in the field of breast cancer research in the world by Lnx Pharma, and in 2015 he was named as No. 8 in the top 100 most influential laboratory medicine professionals in the world by The Pathologist.
He is immediate Past President of the Pathological Society of Great Britain and Ireland. He has been Specialty Advisor to The Royal College of Pathologists and is past Chairman of the UK National Coordinating Committee for Breast Pathology. He has acted as an advisor to the DoH and UICC. He is Medical Director of Source Bioscience plc. In 2011 he was awarded Honorary Fellowship of the Royal College of Pathologists of Australia. He retired from his full-time University and honorary NHS consultant post at the end of August 2015, returning on a part-time basis in October 2015. He serves on the editorial boards of several premier oncology and cancer journals, such as The Journal of Pathology, Histopathology, and BMC Cancer.